278 filings
Page 4 of 14
8-K
9lf9uh
25 Mar 21
Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service
12:00am
S-8
mob67v0u5mog7p8 9mj4
24 Feb 21
Registration of securities for employees
4:49pm
8-K
o43xmoie ys2xfx
24 Feb 21
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
4:01pm
8-K
bns7wr5c03jxv78
8 Jan 21
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
4:02pm
424B5
7kut6t m1
7 Jan 21
Prospectus supplement for primary offering
5:25pm
FWP
x574lqxhrn82kx0 5evv
5 Jan 21
Free writing prospectus
5:20pm
424B5
ge74l v5r
4 Jan 21
Prospectus supplement for primary offering
4:15pm
8-K
yi0zmd ksq5upxl2u1w
22 Dec 20
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
t3orq0ue oui76
7 Dec 20
Other Events
9:00am
8-K
9nvx2m cjnrqkx
5 Nov 20
Fate Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Operational Progress
4:02pm
8-K
s6hhtzcgvbhk0rk
19 Aug 20
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
4:01pm
8-K
mafve0ay
5 Aug 20
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
4:01pm
D
1asayjnmh
6 Jul 20
$50M in equity, sold $50M, 1 investor
3:44pm
424B5
j6m2xfay
10 Jun 20
Prospectus supplement for primary offering
12:00am
8-K
w1d q5r49pbr
9 Jun 20
Fate Therapeutics Announces Proposed Public Offering of Common Stock
9:21pm
424B5
eqds55bpf 4fwhcufj
8 Jun 20
Prospectus supplement for primary offering
4:11pm